ASH Annual Meeting 2021- Focus on Multiple Myeloma

This year’s American Society of Hematology Annual Meeting (ASH) annual meeting is taking place December 11-14, virtually and in-person in Atlanta, Georgia. The 2021 agenda provides attendees with the latest practice-changing advances in the prevention, diagnosis, and management of hematologic disorders.

Look out for coverage of the meeting and click here to learn more about the 2021 ASH Annual Meeting.

Teclistamab Continues to Produce Durable Responses in MajesTEC-1 Trial

The bispecific antibody teclistamab displayed a manageable safety profile at the recommended phase II dose and continued to produce...

Daratumumab-Based Triplet Regimen in Real-World Patients With Relapsed or Refractory Multiple Myeloma

Researchers evaluated real-world data on the combination of daratumumab plus bortezomib and dexamethasone (DVd) after its adoption for treatment...

iStopMM Study: Population-Based Prevalence of Smoldering Multiple Myeloma

Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study identified epidemiological and clinical characteristics of smoldering...

Utility of IMWG Frailty Scoring in Patients With Relapsed/Refractory Multiple Myeloma

While the International Myeloma Working Group (IMWG) Index was validated in scoring patients with newly diagnosed multiple myeloma, its...

Multiple Myeloma and Waldenström Macroglobulinemia Patients Have Impaired COVID-19 Vaccine Responsiveness

According to a poster presented at the 2021 ASH Annual Meeting by Andrew R. Branagan, MD, PhD, and colleagues,...

Four-Drug Regimen of Dara-KRd Plus AHCT and Consolidation Induces MRD Negativity

According to findings presented at the 2021 ASH Annual Meeting, the combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd),...

Hematology and Oncology News

Curated Journal Abstracts